CHRU De Nancy
- Address
- lock Available on a paid plan
Cardiovascular Medicine
The department focuses on cardiovascular diseases, addressing conditions such as acute venous thromboembolism and related clotting disorders.
- Evaluation of full-dose anticoagulant strategies
- Risk assessment of bleeding in patients on antiplatelet therapy
- Optimization of antithrombotic regimens in acute VTE
Ongoing studies aim to improve patient safety by comparing treatment approaches and reducing complications.
Liver Cancer Research
Investigations target hepatocellular carcinoma and metastatic colorectal cancer involving the liver, seeking more effective systemic therapies.
- Combination immunotherapy with checkpoint inhibitors
- Assessment of survival benefits with novel drug regimens
- Exploration of first‑line treatment options for advanced liver tumors
Trials are designed to extend overall survival and improve disease‑free outcomes for patients with liver‑related cancers.
Prostate Cancer Diagnostics
Research advances the use of PSMA PET‑CT imaging to better detect pelvic nodal metastases in high‑risk prostate cancer.
- Sensitivity and specificity evaluation of new radiotracers
- Comparison of imaging results with histopathology
- Impact of early detection on treatment planning
The goal is to refine diagnostic accuracy, enabling personalized therapeutic decisions.
Lymphoma Therapeutics
Clinical work concentrates on Diffuse Large B‑Cell Lymphoma in elderly patients, testing antibody‑based combinations.
- Efficacy of anti‑CD19 antibody with lenalidomide and rituximab
- Response rates after early treatment cycles
- Safety profile in older cohorts
By optimizing regimens, researchers hope to increase remission rates while maintaining tolerability.
Severe Asthma in Children
Studies address severe uncontrolled asthma in pediatric populations, evaluating novel biologic agents.
- Reduction of asthma exacerbations with targeted therapy
- Comparison to placebo in real‑world settings
- Long‑term safety in children under 12
The aim is to provide better control and quality of life for young patients with refractory asthma.
Food Allergy Immunotherapy
The site conducts trials on peanut allergy desensitization using skin‑applied immunotherapy.
- Safety and efficacy of low‑dose peanut patches
- Long‑term tolerance development
- Impact on daily activities of affected children
Successful outcomes could offer a convenient alternative to strict avoidance diets.
ICU Infection Management
Research focuses on ventilator‑acquired pneumonia and the role of immune modulation in critical care.
- Use of recombinant interferon‑gamma alongside antibiotics
- Effect on duration of mechanical ventilation
- Biomarker‑guided patient selection
Findings aim to shorten ICU stays and improve survival for severely ill patients.
Innovative Diagnostic Tools
The department explores advanced analytical and therapeutic equipment to support diverse disease studies.
- Implementation of computer‑aided imaging analysis
- Integration of novel biomarkers into clinical workflows
- Evaluation of new device safety and performance
These efforts underpin the precision medicine approach across multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHRU De Nancy
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE) | Dbv Technologies | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 39 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (2S)-2-[[(1S)-1-Carboxy-5-[[(2S)-2-[[4-[[[(2S)-4-Carboxy-2-[[(2S)-4-Carboxy-2-[(6-(18F)Fluoranylpyridine-3-Carbonyl)Amino]Butanoyl]Amino]Butanoyl]Amino]Methyl]Benzoyl]Amino]-3-Naphthalen-2-Ylpropanoyl]Amino]Pentyl]Carbamoylamino]Pentanedioic Acid | 1 | Unknown | 2024-06-05 | 2024-06-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.